SVB Leerink Equities Analysts Reduce Earnings Estimates for Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) – Analysts at SVB Leerink lowered their Q3 2022 earnings estimates for Hims & Hers Health in a research note issued on Tuesday, August 9th. SVB Leerink analyst J. Zhang now forecasts that the company will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.09). SVB Leerink has a “Underperform” rating and a $5.00 price objective on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is ($0.35) per share. SVB Leerink also issued estimates for Hims & Hers Health’s Q1 2023 earnings at ($0.08) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.27) EPS and FY2024 earnings at ($0.15) EPS.

A number of other research analysts also recently issued reports on the stock. Credit Suisse Group boosted their price objective on shares of Hims & Hers Health from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $7.00 to $8.00 in a research report on Wednesday. Citigroup reduced their price objective on shares of Hims & Hers Health from $9.00 to $6.00 in a research report on Tuesday, May 10th. Finally, Piper Sandler reduced their target price on shares of Hims & Hers Health from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, May 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.14.

Hims & Hers Health Trading Up 4.0 %

Shares of Hims & Hers Health stock opened at $7.09 on Thursday. The company’s fifty day simple moving average is $5.23 and its two-hundred day simple moving average is $4.78. The company has a market cap of $1.45 billion, a P/E ratio of -17.29 and a beta of 0.49. Hims & Hers Health has a 12-month low of $2.72 and a 12-month high of $9.35.

Hims & Hers Health (NYSE:HIMS – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Hims & Hers Health had a negative net margin of 22.22% and a negative return on equity of 23.24%. The company had revenue of $113.60 million during the quarter, compared to analyst estimates of $103.89 million. During the same period in the prior year, the business posted ($0.08) EPS. The firm’s revenue was up 89.0% compared to the same quarter last year.

Insider Buying and Selling

In other news, Director Jules A. Maltz purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The shares were bought at an average price of $3.99 per share, for a total transaction of $199,500.00. Following the purchase, the director now directly owns 50,000 shares in the company, valued at approximately $199,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Jules A. Maltz purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The shares were bought at an average price of $3.99 per share, for a total transaction of $199,500.00. Following the purchase, the director now directly owns 50,000 shares in the company, valued at approximately $199,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Irene Becklund sold 19,331 shares of the company’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $5.00, for a total transaction of $96,655.00. Following the completion of the transaction, the insider now owns 13,717 shares in the company, valued at approximately $68,585. The disclosure for this sale can be found here. 35.22% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. Captrust Financial Advisors lifted its stake in Hims & Hers Health by 1,827.4% during the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after acquiring an additional 6,414 shares during the period. Sciencast Management LP bought a new position in Hims & Hers Health during the 1st quarter valued at about $53,000. Evoke Wealth LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at about $62,000. ProShare Advisors LLC bought a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $62,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $65,000. Institutional investors own 57.22% of the company’s stock.

Hims & Hers Health Company Profile

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.